191 related articles for article (PubMed ID: 17525625)
1. Immunohistochemical staining of papillary breast lesions.
Troxell ML; Masek M; Sibley RK
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):145-53. PubMed ID: 17525625
[TBL] [Abstract][Full Text] [Related]
2. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.
Tse GM; Tan PH; Lui PC; Gilks CB; Poon CS; Ma TK; Law BK; Lam WW
J Clin Pathol; 2007 Mar; 60(3):315-20. PubMed ID: 16698948
[TBL] [Abstract][Full Text] [Related]
3. Use of a novel marker, calponin, for myoepithelial cells in fine-needle aspirates of papillary breast lesions.
Mosunjac MB; Lewis MM; Lawson D; Cohen C
Diagn Cytopathol; 2000 Sep; 23(3):151-5. PubMed ID: 10945900
[TBL] [Abstract][Full Text] [Related]
4. Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas.
Hill CB; Yeh IT
Am J Clin Pathol; 2005 Jan; 123(1):36-44. PubMed ID: 15762278
[TBL] [Abstract][Full Text] [Related]
5. CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast.
Tse GM; Tan PH; Ma TK; Gilks CB; Poon CS; Law BK
J Clin Pathol; 2005 Nov; 58(11):1185-8. PubMed ID: 16254109
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathologic and immunohistochemical study of 187 cases of intraductal papillary neoplasm of breast].
Zhang H; Xiong Y; Zhang S; Zhang Y; Wang YH; Li T
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):726-31. PubMed ID: 22336153
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
Werling RW; Hwang H; Yaziji H; Gown AM
Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
[TBL] [Abstract][Full Text] [Related]
8. The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast.
Ding Y; Ruan Q
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(4):405-7. PubMed ID: 17120733
[TBL] [Abstract][Full Text] [Related]
9. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
Ichihara S; Fujimoto T; Hashimoto K; Moritani S; Hasegawa M; Yokoi T
Pathol Int; 2007 Mar; 57(3):126-32. PubMed ID: 17295644
[TBL] [Abstract][Full Text] [Related]
10. Myoepithelial cells in solid variant of intraductal papillary carcinoma of the breast: a potential diagnostic pitfall and a proposal of an immunohistochemical panel in the differential diagnosis with intraductal papilloma with usual ductal hyperplasia.
Moritani S; Ichihara S; Kushima R; Okabe H; Bamba M; Kobayashi TK; Hattori T
Virchows Arch; 2007 May; 450(5):539-47. PubMed ID: 17377808
[TBL] [Abstract][Full Text] [Related]
11. Use of p63 and CD10 in the differential diagnosis of papillary neoplasms of the breast.
de Moraes Schenka NG; Schenka AA; de Souza Queiroz L; de Almeida Matsura M; Vassallo J; Alvarenga M
Breast J; 2008; 14(1):68-75. PubMed ID: 18086274
[TBL] [Abstract][Full Text] [Related]
12. Myoepithelial cell cocktail (p63+SMA) for the evaluation of sclerosing breast lesions.
Pavlakis K; Zoubouli C; Liakakos T; Messini I; Keramopoullos A; Athanassiadou S; Kafousi M; Stathopoulos EN
Breast; 2006 Dec; 15(6):705-12. PubMed ID: 16384708
[TBL] [Abstract][Full Text] [Related]
13. CD44s as a surrogate marker for distinguishing intraductal papilloma from papillary carcinoma of the breast.
Saddik M; Lai R
J Clin Pathol; 1999 Nov; 52(11):862-4. PubMed ID: 10690183
[TBL] [Abstract][Full Text] [Related]
14. p63 expression in benign and malignant breast lesions.
Stefanou D; Batistatou A; Nonni A; Arkoumani E; Agnantis NJ
Histol Histopathol; 2004 Apr; 19(2):465-71. PubMed ID: 15024707
[TBL] [Abstract][Full Text] [Related]
15. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers.
Collins LC; Carlo VP; Hwang H; Barry TS; Gown AM; Schnitt SJ
Am J Surg Pathol; 2006 Aug; 30(8):1002-7. PubMed ID: 16861972
[TBL] [Abstract][Full Text] [Related]
16. Papillary neoplasia of the breast: immunohistochemically defined myoepithelial cells in the diagnosis of benign and malignant papillary breast neoplasms.
Raju UB; Lee MW; Zarbo RJ; Crissman JD
Mod Pathol; 1989 Nov; 2(6):569-76. PubMed ID: 2479944
[TBL] [Abstract][Full Text] [Related]
17. A useful immunohistochemical approach to evaluate intraductal proliferative lesions of the breast and to predict their prognosis.
Omi Y; Yamamoto T; Okamoto T; Obara T; Kobayashi M
Histol Histopathol; 2011 Jan; 26(1):79-86. PubMed ID: 21117029
[TBL] [Abstract][Full Text] [Related]
18. Basal/myoepithelial cells in chronic sinusitis, respiratory epithelial adenomatoid hamartoma, inverted papilloma, and intestinal-type and nonintestinal-type sinonasal adenocarcinoma: an immunohistochemical study.
Ozolek JA; Barnes EL; Hunt JL
Arch Pathol Lab Med; 2007 Apr; 131(4):530-7. PubMed ID: 17425380
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
Popnikolov NK; Cavone SM; Schultz PM; Garcia FU
Mod Pathol; 2005 Dec; 18(12):1535-41. PubMed ID: 16258511
[TBL] [Abstract][Full Text] [Related]
20. Loss of myoepithelium is variable in solid papillary carcinoma of the breast.
Nicolas MM; Wu Y; Middleton LP; Gilcrease MZ
Histopathology; 2007 Nov; 51(5):657-65. PubMed ID: 17927587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
